How to Stop Excess Hair Shedding Before Starting Minoxidil - How To Stop Telogen Effluvium Shedding
- 1 day ago
- 6 min read
Updated: 11 hours ago
The GrowBack Stabilisation Approach for Telogen Effluvium Using Anagen Advanced, TrichoRx24 and PGD2-Blocking Scalp Therapy
Why Stabilising Hair Shedding Matters Before Starting Minoxidil
One of the biggest mistakes people make when experiencing sudden hair shedding is immediately jumping into aggressive hair-growth stimulation without first stabilising the follicle environment.
In clinical practice, many individuals presenting with excessive shedding are experiencing some form of telogen effluvium (TE). This is a reactive hair shedding condition where a higher proportion of follicles prematurely shift from the anagen (growth) phase into the telogen (resting and shedding) phase.
The result is often dramatic and emotionally distressing.
You may notice:
Large amounts of hair in the shower
Increased shedding on pillows and clothing
Loss of density around the crown and temples
Diffuse thinning across the scalp
Increased scalp visibility
Heightened anxiety around washing or brushing hair
The instinct is usually to “force regrowth” as quickly as possible. However, this can sometimes worsen the psychological stress cycle and destabilise the scalp further.
So, How To Stop Telogen Effluvium Shedding?
At GrowBack, our approach focuses on one key principle:
Stabilisation first. Growth second.
Before introducing stronger growth stimulants such as minoxidil, the initial aim should be to:
Reduce the trigger burden
Support the follicle biologically
Calm excessive shedding pathways
Improve scalp signalling
Create a healthier environment for future regrowth treatments
This is where the GrowBack Stabilisation Process becomes clinically valuable.
Understanding Telogen Effluvium
Telogen effluvium is not simply “hair loss”. It is a disruption of the normal hair cycle.
Under normal circumstances, approximately 85–90% of scalp hairs remain in the anagen growth phase, while 10–15% remain in telogen. In telogen effluvium, physiological or psychological stress causes a larger proportion of follicles to synchronously enter telogen prematurely.
Common triggers include:
Emotional stress
Illness or infection
Surgery
Rapid weight loss
Nutritional deficiency
Hormonal fluctuations
Perimenopause
Thyroid dysfunction
Medication changes
Inflammatory stress
GLP-1 agonist weight-loss medication use
Postpartum changes
Importantly, many clients experiencing TE also develop secondary androgen-sensitive thinning if the shedding remains uncontrolled over time.
This is why early stabilisation matters.
The GrowBack Stabilisation Process
The GrowBack Stabilisation Process combines:
Anagen Advanced by HINNAO® at night
TrichoRx24 in the morning
PGD2-blocking scalp support
Stress reduction and trigger management
Delayed introduction of personalised minoxidil therapy
This protocol is designed to help calm excessive shedding before attempting aggressive follicular stimulation.
Step 1: Identify and Reduce the Stress Trigger
No hair treatment works effectively if the original trigger remains unaddressed.
Clients experiencing TE should first investigate potential drivers including:
Nutritional deficiency
Ferritin depletion
Thyroid imbalance
Hormonal changes
Chronic stress
Sleep disruption
Caloric restriction
Illness recovery
Medication-related shedding
In many cases, the hair follicle is reacting appropriately to systemic stress.
Attempting to stimulate aggressive regrowth without reducing this burden can lead to inconsistent outcomes and heightened shedding anxiety.
Step 2: Protect and Stabilise the Follicle
Morning Support: TrichoRx24
TrichoRx24 is designed as a broad-spectrum nutritional and antioxidant support formulation targeting multiple pathways associated with hair follicle stress.
The formulation includes ingredients selected to support:
Oxidative stress balance
Circulation
Inflammatory modulation
DHT pathway support
Collagen synthesis
Cellular energy pathways
With TE, the aim is not immediate forced regrowth. The goal is to create a more resilient follicular environment capable of sustaining future anagen activity.
Night Support: Anagen Advanced by HINNAO®
Night-time is an ideal period for follicular recovery support due to the body's nocturnal repair processes.
Anagen Advanced contains:
Hydrolysed bovine collagen peptides
Biotin
Zinc picolinate
Methyl folate
Astaxanthin
These ingredients contribute to normal hair physiology through several mechanisms:
Biotin
Biotin contributes to the maintenance of normal hair and skin.
Zinc
Zinc contributes to normal hair maintenance and protection against oxidative stress.
Collagen Peptides
Collagen-derived amino acids provide structural support relevant to connective tissue and extracellular matrix integrity surrounding the follicle.
Methyl Folate
Supports normal cell division and rapidly dividing tissues.
Astaxanthin
Functions as a carotenoid antioxidant that may help reduce oxidative stress burden.
The liposomal sublingual delivery system used by HINNAO® is designed to improve absorption kinetics through mucosal uptake.
Step 3: Introduce PGD2-Blocking Scalp Therapy
One of the most overlooked aspects of excessive shedding is the role of scalp signalling molecules.
What is PGD2?
Prostaglandin D2 (PGD2) is a lipid signalling molecule associated with inflammatory and inhibitory hair-growth pathways.
Research has demonstrated elevated PGD2 levels in balding scalp tissue, with evidence suggesting it may inhibit hair growth through GPR44 receptor signalling.
In practical clinical terms, increased PGD2 activity may contribute to:
Follicular miniaturisation
Reduced anagen duration
Increased shedding tendency
Scalp inflammation signalling
This is why GrowBack often incorporates a PGD2-blocking scalp application during the stabilisation phase.
The objective is not simply “growth stimulation”, but rather improving the follicular environment before introducing stronger regenerative strategies.
Why We Often Delay Minoxidil Initially
Minoxidil remains one of the most evidence-supported therapies for hair growth. However, introducing it too early during active TE can sometimes create unnecessary psychological distress.
The Minoxidil Shedding Phase
When minoxidil begins shifting follicles into anagen, some clients experience temporary synchronised shedding.
For individuals already panicking about hair loss, this can feel catastrophic.
This is why stabilisation-first protocols are clinically valuable.
By first calming shedding and supporting follicular resilience, you can tolerate future minoxidil therapy more successfully.
Step 4: Begin Personalised Minoxidil Therapy
Once shedding has stabilised, personalised minoxidil-based growth therapy can be introduced more strategically.
This is where TrichoDNA testing becomes highly valuable.
Why TrichoDNA Testing Matters
Not all clients respond equally to minoxidil.
One of the key reasons is genetic variability in:
Sulfotransferase enzyme activity
Inflammatory pathways
Prostaglandin balance
Circulation pathways
Oxidative stress handling
Androgen sensitivity
The Importance of Sulfotransferase Activity
Minoxidil is a pro-drug.
It requires conversion into active minoxidil sulfate by sulfotransferase enzymes within the follicle.
Clients with lower sulfotransferase activity may respond poorly to standard minoxidil formulations.
TrichoDNA testing helps identify pathways involved in:
Minoxidil responsiveness
PGD2 signalling
DHT sensitivity
Collagen support pathways
Oxidative stress burden
Circulation support
This allows GrowBack to formulate more personalised treatment strategies rather than relying on generic one-size-fits-all solutions.
Why We Recommend Starting TrichoDNA Testing Early
TrichoDNA results typically take approximately 3–4 weeks.
For this reason, we recommend:
Begin the DNA test immediately while simultaneously starting the GrowBack Stabilisation Process.
This ensures you are not “waiting without treatment”.
Instead, begin stabilising shedding immediately while more advanced personalised treatment planning is being developed in the background.
The Clinical Philosophy Behind the GrowBack Approach
The GrowBack philosophy is based on the principle that:
A stressed follicle should first be protected before aggressively stimulated.
Many online platforms immediately push high-strength growth products without assessing:
Shedding patterns
Inflammatory status
Scalp signalling
Stress burden
DNA pathways
Nutritional resilience
In reality, stabilisation often determines whether long-term regrowth becomes sustainable.
Who May Benefit From This Approach?
This protocol may be suitable for individuals experiencing:
Telogen effluvium
Sudden diffuse shedding
Post-stress hair loss
Weight-loss related shedding
Perimenopausal shedding
Post-illness hair loss
Early-stage thinning
Minoxidil anxiety
Reactive shedding after medication changes
Final Thoughts
Hair shedding can feel emotionally overwhelming, particularly when it appears sudden or relentless.
However, successful treatment is not always about starting the strongest growth stimulant immediately.
In many cases, the most intelligent strategy is:
Stabilise first. Personalise second. Stimulate growth third.
By combining:
Anagen Advanced at night
TrichoRx24 in the morning
PGD2-blocking scalp therapy
Stress reduction
TrichoDNA testing
Personalised minoxidil planning
The follicle environment can often be supported more effectively before moving into advanced regrowth protocols.
This phased strategy aims to reduce panic-driven treatment decisions and improve long-term follicular resilience.
References
Almohanna, H.M., Ahmed, A.A., Tsatalis, J.P. and Tosti, A. (2019) ‘The role of vitamins and minerals in hair loss: A review’, Dermatology and Therapy, 9(1), pp. 51–70.
Garza, L.A., Liu, Y., Yang, Z. et al. (2012) ‘Prostaglandin D2 inhibits hair growth and is elevated in bald scalp of men with androgenetic alopecia’, Science Translational Medicine, 4(126), pp. 126ra34.
Headington, J.T. (1993) ‘Telogen effluvium. New concepts and review’, Archives of Dermatology, 129(3), pp. 356–363.
Messenger, A.G. and Sinclair, R. (2006) ‘Follicular miniaturization in female pattern hair loss: Clinicopathological correlations’, British Journal of Dermatology, 155(5), pp. 926–930.
Mirmirani, P. and Bergfeld, W.F. (2010) ‘Telogen effluvium’, Dermatologic Clinics, 31(1), pp. 35–46.
Rossi, A., Cantisani, C., Melis, L. et al. (2012) ‘Minoxidil use in dermatology, side effects and recent patents’, Recent Patents on Inflammation & Allergy Drug Discovery, 6(2), pp. 130–136.
Suchonwanit, P., Thammarucha, S. and Leerunyakul, K. (2019) ‘Minoxidil and its use in hair disorders: A review’, Drug Design, Development and Therapy, 13, pp. 2777–2786.
Trueb, R.M. (2015) ‘Molecular mechanisms of androgenetic alopecia’, Experimental Gerontology, 68, pp. 5–9.
Wambier, C.G. and King, B.A. (2019) ‘Rethinking the role of prostaglandins in hair growth’, Journal of the American Academy of Dermatology, 80(2), pp. e45–e46.
Wolff, H., Fischer, T.W. and Blume-Peytavi, U. (2016) ‘The diagnosis and treatment of hair and scalp diseases’, Deutsches Ärzteblatt International, 113(21), pp. 377–386.
Comments